SIIC MEDTECH<08018> - Results Announcement
SIIC Medical Science and Technology (Group) Limited announced on 09/05/2003:
(stock code: 08018 )
Year end date: 31/12/2003
Currency: HKD
Auditors' Report: N/A
Review of Interim Report by: Audit Committee
Important Note:
This result announcement form only contain extracted information
from and should be read in conjunction with the detailed results
announcement of the issuer, which can be view on the GEM website
at http://www.hkgem.com
(Unaudited )
(Unaudited ) Last
Current Corresponding
Period Period
from 01/01/2003 from 01/01/2002
to 31/03/2003 to 31/03/2002
Note ('000 ) ('000 )
Turnover 2 : 325,740 237,420
Profit/(Loss) from Operations : 53,316 46,428
Finance cost : (70) 0
Share of Profit/(Loss) of
Associates : 3,337 3,795
Share of Profit/(Loss) of
Jointly Controlled Entities : (286) (352)
Profit/(Loss) after Tax & MI : 21,067 18,864
% Change over Last Period : +11.7 %
EPS/(LPS)-Basic (in dollars) 3 : 0.034 0.03
-Diluted (in dollars) 3 : N/A N/A
Extraordinary (ETD) Gain/(Loss) : 0 0
Profit/(Loss) after ETD Items : 21,067 18,864
1st Quarterly Dividend : N/A N/A
per Share
(Specify if with other : N/A N/A
options)
B/C Dates for
1st Quarterly Dividend : N/A
Payable Date : N/A
B/C Dates for (-)
General Meeting : N/A
Other Distribution for : N/A
Current Period
B/C Dates for Other
Distribution : N/A
For and on behalf of
SIIC Medical Science and Technology (Group) Limited
Name : Wong Mei Ling, Marina
Title : Company Secretary
Responsibility statement
The directors of the Company (the "Directors") as at the date hereof
hereby collectively and individually accept full responsibility for
the accuracy of the information contained in this results announcement
form (the "Information") and confirm, having made all reasonable
inquiries, that to the best of their knowledge and belief the
Information are accurate and complete in all material respects and
not misleading and that there are no other matters the omission of
which would make the Information herein inaccurate or misleading. The
Directors acknowledge that the Stock Exchange has no responsibility
whatsever with regard to the Information and undertake to indemnify
the Exchange against all liability incurred and all losses suffered
by the Exchange in connection with or relating to the Information.
Remarks:
1. Basis of preparation
The principal accounting policies adopted in preparing the unaudited
consolidated results of the Group conform with accounting principles
generally accepted in Hong Kong and accounting standards issued by
the Hong Kong Society of Accountants. The consolidated income
statement have been prepared under the historical cost convention
as modified for revaluation of certain properties.
2. Turnover
Turnover represents the net amounts received and receivable for
goods sold by the Group to outside customers during the period.
For the period ended 31st March, 2003 and 2002, the Group was engaged
in the manufacture and sale of Chinese medicine and health
supplement products. More than 90% of the Group's turnover,
contribution to operating profit and assets was attributable to this
business segment and located in the PRC.
3. Earnings per share
The calculation of the basic earnings per share for the period is
based on the following data:
For the three months ended 31st March
2003 2002
Earnings:
Net Profit for the period and
earnings for the purpose of
basic earnings per share HK$21,067,000 HK$18,864,000
============= =============
Number of shares :
Weighted average number of
ordinary shares for the
purpose of basic earnings
per share 620,000,000 620,000,000
=========== ===========
Diluted earnings per share is not presented as there were no
dilutive potential ordinary shares in existence during the
period.
|